Since June 2019, the cardiac catheterization lab has offered plaque modification therapy to select patients undergoing percutaneous coronary intervention (PCI). We first introduced rotational atherectomy and now include intravascular lithotripsy to patients with heavily calcified lesions. Addressing significant coronary calcification, which is more prevalent with advanced age, kidney disease, diabetes and previous coronary bypass surgery, can improve the effectiveness of drug-eluting stents.